ACTIVE_NOT_RECRUITING

Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease

Conditions

Alzheimer Dementia Presenile Alzheimer Dementia Aging

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The objective of this study is to conduct a pilot, randomized sham-controlled trials to determine the feasibility and effects of a 10-session personalized tDCS intervention targeting the left dorsolateral prefrontal cortex on cognitive function, dual task standing and walking, and other metrics of mobility in 24 older adults with mild AD living in supportive housing.

Official Title

Modulating Brain Activity to Improve Cognitive-motor Function in Alzheimer's Disease

Quick Facts

Study Start:2020-01-31

Study Completion:2026-01-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT04289402

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:65 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Men and women aged 65 and older living within supportive housing facilities * Mild Alzheimer's disease (AD) defined by the combination of 1) at least mild cognitive impairment defined as a modified TICS score of ≤ 34, 2) informant-report of Instrumental Activities of Daily Living impairment as defined as a score of ≥ 6 on the NACC Functional Activities Questionnaire, and 3) a Clinical Dementia Rating score of 1.	* Inability to secure informant participation * Unwillingness to cooperate or participate in the study protocol * An inability to ambulate without the assistance of another person (canes or walkers allowed) * A clinical history of stroke, Parkinson's disease or parkinsonian symptoms, multiple sclerosis, normal pressure hydrocephalus, or other neurological conditions outside of mild AD. * Any report of severe lower-extremity arthritis or physician-diagnosis of peripheral neuropathy * Use of antipsychotics, anti-seizure, benzodiazepines, or other neuroactive medications * Severe depression defined by a Center for Epidemiologic Studies Depression scale score greater than 16 * Any report of physician-diagnosis of schizophrenia, bipolar disorder, or other psychiatric illness * Contraindications to MRI or tDCS, including reported seizure within the past two years, use of neuropsychological-active drugs, the risk of metal objects anywhere in the body, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemakers, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp

Inclusion Criteria

Exclusion Criteria

* Men and women aged 65 and older living within supportive housing facilities
* Mild Alzheimer's disease (AD) defined by the combination of 1) at least mild cognitive impairment defined as a modified TICS score of ≤ 34, 2) informant-report of Instrumental Activities of Daily Living impairment as defined as a score of ≥ 6 on the NACC Functional Activities Questionnaire, and 3) a Clinical Dementia Rating score of 1.

* Inability to secure informant participation
* Unwillingness to cooperate or participate in the study protocol
* An inability to ambulate without the assistance of another person (canes or walkers allowed)
* A clinical history of stroke, Parkinson's disease or parkinsonian symptoms, multiple sclerosis, normal pressure hydrocephalus, or other neurological conditions outside of mild AD.
* Any report of severe lower-extremity arthritis or physician-diagnosis of peripheral neuropathy
* Use of antipsychotics, anti-seizure, benzodiazepines, or other neuroactive medications
* Severe depression defined by a Center for Epidemiologic Studies Depression scale score greater than 16
* Any report of physician-diagnosis of schizophrenia, bipolar disorder, or other psychiatric illness
* Contraindications to MRI or tDCS, including reported seizure within the past two years, use of neuropsychological-active drugs, the risk of metal objects anywhere in the body, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemakers, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp

Contacts and Locations

Principal Investigator

Brad Manor, PhD

PRINCIPAL_INVESTIGATOR

Hebrew SeniorLife

Study Locations (Sites)

Hebrew Rehabilitation Center

Roslindale, Massachusetts, 02131

United States

Collaborators and Investigators

Sponsor: Hebrew SeniorLife

Brad Manor, PhD, PRINCIPAL_INVESTIGATOR, Hebrew SeniorLife

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-01-31

Study Completion Date2026-01-31

Study Record Updates

Study Start Date2020-01-31

Study Completion Date2026-01-31

Terms related to this study

Keywords Provided by Researchers

Aging

Additional Relevant MeSH Terms

Alzheimer Dementia
Presenile Alzheimer Dementia
Aging